Ensysce Biosciences Inc Market Cap ($8.19 Million)
Market Cap & Net Worth: Ensysce Biosciences Inc (ENSC)
Ensysce Biosciences Inc market cap. Ensysce Biosciences Inc (NASDAQ:ENSC) has a market capitalization of $8.19 Million ($8.19 Million) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27440 globally and #5694 in its home market, demonstrating a -17.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ensysce Biosciences Inc's stock price $0.42 by its total outstanding shares 19456794 (19.46 Million). Also see cash efficiency ratio of Ensysce Biosciences Inc for how efficiently the company converts equity into cash flow.
Ensysce Biosciences Inc Market Cap History (2018–2026)
Ensysce Biosciences Inc market cap history from 2018 to 2026. Data shows change from $45.86 Billion to $8.19 Million (-62.93% CAGR). Check ENSC share price today for real-time trading data and today's change.
Index Memberships
Ensysce Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #777 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #2517 of 3165 |
Weight: Ensysce Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ensysce Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ensysce Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Ensysce Biosciences Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.53x
Ensysce Biosciences Inc's market cap is 3.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $48.66 Billion | $1.76 Million | $1.48 Million | 27584.26x | 32957.92x |
| 2020 | $58.07 Billion | $3.93 Million | $56.77K | 14770.38x | 1022819.36x |
| 2021 | $21.95 Billion | $3.53 Million | -$29.15 Million | 6215.24x | N/A |
| 2022 | $175.11 Million | $2.52 Million | -$24.96 Million | 69.40x | N/A |
| 2023 | $20.62 Million | $2.23 Million | -$10.61 Million | 9.24x | N/A |
| 2024 | $158.38 Million | $5.21 Million | -$7.99 Million | 30.40x | N/A |
| 2025 | $17.90 Million | $5.07 Million | -$10.18 Million | 3.53x | N/A |
Competitor Companies of ENSC by Market Capitalization
Companies near Ensysce Biosciences Inc in the global market cap rankings as of November 1, 2026. Also see Ensysce Biosciences Inc total assets for a full breakdown of the balance sheet.
Key companies related to Ensysce Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Ensysce Biosciences Inc (2018–2026)
Market capitalization of Ensysce Biosciences Inc from 2018 to today. Between 2018 and today, Ensysce Biosciences Inc's market cap moved from $45.86 Billion to $ 8.19 Million, with a yearly change of -62.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.19 Million | -54.24% |
| 2025 | $17.90 Million | -88.70% |
| 2024 | $158.38 Million | +667.92% |
| 2023 | $20.62 Million | -88.22% |
| 2022 | $175.11 Million | -99.20% |
| 2021 | $21.95 Billion | -62.20% |
| 2020 | $58.07 Billion | +19.33% |
| 2019 | $48.66 Billion | +6.11% |
| 2018 | $45.86 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Ensysce Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.19 Million USD |
| MoneyControl | $8.19 Million USD |
| MarketWatch | $8.19 Million USD |
| marketcap.company | $8.19 Million USD |
| Reuters | $8.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR)… Read more